The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Utility Of Adenosine Stress Cardiac Magnetic Resonance Imaging Following ST Elevation Myocardial Infarction Post Primary Angioplasty
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Heart attacks remain the leading cause of death in the western world. Many patients presenting with an acute heart attack have more than one significant narrowing in the blood vessel. After treatment of the culprit vessel, a robust non invasive imaging technique such as cardiac MRI allows us to study of the extent of damage from the heart attack. In addition, it also enables us to determine the functional significance of the non culprit vessel. This will help guide the management of these patien ....Heart attacks remain the leading cause of death in the western world. Many patients presenting with an acute heart attack have more than one significant narrowing in the blood vessel. After treatment of the culprit vessel, a robust non invasive imaging technique such as cardiac MRI allows us to study of the extent of damage from the heart attack. In addition, it also enables us to determine the functional significance of the non culprit vessel. This will help guide the management of these patients.Read moreRead less
Identification Of Biomarkers Predictive Of Response To Bevacizumab In Patients With Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$32,628.00
Summary
Despite multimodality therapy, the median survival for patients diagnosed with high grade malignant brain tumours is only 12 months. Patient response to therapy is highly variable. Our aim is to develop a “genetic signature” that will predict response to bevacuzimab (an agent targeting blood vessel formation). Identifying patients who will respond to bevacuzimab will save many patients from a toxic and costly therapy, from which they will derive little benefit.